The Need for Optimized Patient Treatment Recommendations: How GenomOncology Utilizes Prior Interventions Eligibility Criteria in Treatment Matching
No two cancer patients are the same. Some patients have yet to undergo any treatments, while others have failed multiple lines of treatment. However, no matter what journey a patient has been through, their medical history can impact their eligibility for further treatment opportunities.
To avoid recommending patients to clinical trials or therapies they may not be eligible for, GenomOncology includes all prior intervention eligibility data, along with clinical and biomarker data, in its automated treatment matching and identification process. To break down how GenomOncology utilizes prior medical interventions within its platform, join GenomOncology’s Chief Technology Officer, Ian Maurer, and Director of Product Management, James Cole, PhD on Wednesday, June 29 at 12 pm ET for an on-demand webinar, where they detail:
-
The importance of prior medical interventions in precision oncology.
-
How GenomOncology’s precision oncology solutions utilize patients’ prior medical interventions and clinical history within its treatment matching algorithm.
-
A patient case study, comparing how a patient is matched with prior medical interventions considered versus without.
Featured Presenters
With over 20 years of software development and leadership experience, Ian leads the technical innovation at GenomOncology. Ian created GenomOncology’s Precision Oncology Platform, and continues to innovate on the platform and GO solution offerings to ensure our precision oncology solutions best serve users.
James Cole has over a decade of experience in precision oncology, making him integral in GenomOncology's understanding of the field of clinical genomics. Cole works across GenomOncology’s Precision Oncology Platform (POP), ensuring all our precision oncology solutions include the necessary precision oncology data sets in order to inform decision support and streamline patient treatment analysis and research.